Compounds > darutigenol
Page last updated: 2024-12-10

darutigenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

darutigenol: from Siegesbeckia glabrescens Mak; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3037565
CHEMBL ID1076911
SCHEMBL ID10246714
MeSH IDM0173894

Synonyms (21)

Synonym
darutigenol
5940-00-1
1-(7-hydroxy-2,4b,8,8-tetramethyl-4,4a,5,6,7,8a,9,10-octahydro-3h-phenanthren-2-yl)ethane-1,2-diol
(1r)-1-[(2s,4ar,4bs,7r,8as)-7-hydroxy-2,4b,8,8-tetramethyl-4,4a,5,6,7,8a,9,10-octahydro-3h-phenanthren-2-yl]ethane-1,2-diol
CHEMBL1076911
S9494
1,2-ethanediol, 1-(2,3,4,4a,4b,5,6,7,8,8a,9,10-dodecahydro-7-hydroxy-2,4b,8,8-tetramethyl-2-phenanthrenyl)-, (2s-(2alpha(s*),4abeta,4balpha,7alpha,8abeta))-
nsc 310619
SCHEMBL10246714
AC-34899
AKOS032948406
HY-N3003
FS-8846
mfcd16621011
CS-0022902
bdbm50465851
XTZ5NBR55T
(1r)-1-[(2s,4ar,4bs,7r,8as)-2,3,4,4a,4b,5,6,7,8,8a,9,10-dodecahydro-7-hydroxy-2,4b,8,8-tetramethyl-2-phenanthrenyl]-1,2-ethanediol
darutoside aglycon
1,2-ethanediol, 1-[(2s,4ar,4bs,7r,8as)-2,3,4,4a,4b,5,6,7,8,8a,9,10-dodecahydro-7-hydroxy-2,4b,8,8-tetramethyl-2-phenanthrenyl]-, (1r)-
EX-A8002E

Research Excerpts

Overview

Darutigenol is a natural active product derived from the Chinese herbal medicine Sigesbeckia glabrescens (Makino)

ExcerptReferenceRelevance
"Darutigenol (DL) is a natural active product derived from the Chinese herbal medicine Sigesbeckia glabrescens (Makino) Makino. "( An integrated network pharmacology approach reveals that Darutigenol reduces inflammation and cartilage degradation in a mouse collagen-induced arthritis model by inhibiting the JAK-STAT3 pathway.
Bao, TR; Gao, XX; He, XL; Jia, JM; Sun, XD; Wang, AH; Wang, Y; Yan, H; Yang, YC; Zhao, L; Zhu, SY, 2023)		2.6

Dosage Studied

ExcerptRelevanceReference
" Darutoside possesses the activity of termination of early pregnancy in experimental rats at a dosage of 20-40 mg/kg."( [Studies on antifertility constituents of Siegesbeckia glabrescens Mak].
Chen, M; Dong, XY; Huang, DX; Jin, W; Li, HT; Shen, SM, 1989)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Coagulation factor XHomo sapiens (human)IC50 (µMol)11.41800.00030.593710.0000AID1414363
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1437542Antiinvasive activity in human MDA-MB-231 cells assessed as inhibition of EGF-induced cell invasion after 3.5 hrs2017Journal of natural products, 01-27, Volume: 80, Issue:1
ent-Strobane and ent-Pimarane Diterpenoids from Siegesbeckia pubescens.
AID469807Cytotoxicity against rat HSC-T6 cells after 44 hrs by MTT assay2010Journal of natural products, Jan, Volume: 73, Issue:1
ent-kaurane and ent-pimarane diterpenoids from Siegesbeckia pubescens.
AID1443648Inhibition of EGF-induced invasion of human MDA-MB-231 cells by MTT assay2017Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
Isolation and characterization of diterpene glycosides from Siegesbeckia pubescens.
AID1437541Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay2017Journal of natural products, 01-27, Volume: 80, Issue:1
ent-Strobane and ent-Pimarane Diterpenoids from Siegesbeckia pubescens.
AID469808Cytotoxicity against human HeLa cells after 44 hrs by MTT assay2010Journal of natural products, Jan, Volume: 73, Issue:1
ent-kaurane and ent-pimarane diterpenoids from Siegesbeckia pubescens.
AID1414363Inhibition of human coagulation factor 10a using Z-D-Arg-Gly-Arg-pNA.2HCl as substrate preincubated for 15 mins followed by substrate addition by UV absorption assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
Semisynthesis of ent-norstrobane diterpenoids as potential inhibitor for factor Xa.
AID469809Cytotoxicity against mouse B16 cells after 44 hrs by MTT assay2010Journal of natural products, Jan, Volume: 73, Issue:1
ent-kaurane and ent-pimarane diterpenoids from Siegesbeckia pubescens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.13 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		2.5520chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
acrylamide
[no description available]		2.0710acrylamides;
N-acylammonia;
primary carboxamide		alkylating agent;
carcinogenic agent;
Maillard reaction product;
mutagen;
neurotoxin
ethylene dimethacrylate
ethylene glycol dimethacrylate : The enoate ester that is the 1,2-bis(methacryloyl) derivative of ethylene glycol.		2.0710enoate esterallergen;
cross-linking reagent;
polymerisation monomer
tetrahydrofuran
oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.		2.0710cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0510taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
edoxaban
edoxaban : A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.		2.1710chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor
kirenol
kirenol: an antirheumatic agent isolated from Siegebeckia; structure in first source		3.0240diterpenoid
darutoside
darutoside: from Siegesbeckia glabrescens Mak; RN given refers to (2R-(2alpha,4aalpha,4bbeta,7alpha(R*),10abeta))		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.1510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1510
Adjuvant Arthritis
[description not available]		02.610
Rheumatoid Arthritis
[description not available]		02.610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.610
Innate Inflammatory Response
[description not available]		02.610
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.610
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		07.610